- $801.14m
- $929.71m
- $139.91m
- 47
- 18
- 53
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 17.88 | ||
| Price to Tang. Book | 17.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.94% | ||
| Return on Equity | -133.29% | ||
| Operating Margin | -14.81% | ||
Financial Summary
| Year End 30th Apr | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 59.7 | 95.87 | 119.6 | 149.27 | 139.91 | 163.11 | 190.45 | 21.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +3194.55 | -99.78 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Directors
- Joseph Carleone NEC (75)
- Nicholas Green PRE (57)
- Daniel Hart CFO (47)
- Richard Richieri COO (51)
- Mark Ziebell VPR (57)
- Matthew Kwietniak OTH
- Richard Hancock DRC (62)
- Esther Alegria IND (63)
- Catherine Mackey IND (65)
- Gregory Sargen IND (56)
- Jeanne Thoma IND (61)
- Last Annual
- April 30th, 2024
- Last Interim
- October 31st, 2024
- Incorporated
- September 25th, 1996
- Public Since
- October 27th, 1993
- No. of Shareholders
- 609
- No. of Employees
- 371
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 64,142,509
- Address
- 14191 MYFORD ROAD, TUSTIN, 92780
- Web
- https://avidbio.com/
- Phone
- +1 7145086100
- Contact
- Stephanie Diaz
- Auditors
- Ernst & Young LLP
Latest News for CDMO
Upcoming Events for CDMO
Q3 2025 Avid Bioservices Inc Earnings Release
Q4 2025 Avid Bioservices Inc Earnings Release
Similar to CDMO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Aptose Biosciences
NASDAQ Capital Market
FAQ
As of Today at 03:41 UTC, shares in Avid Bioservices are trading at $12.49. This share price information is delayed by 15 minutes.
Shares in Avid Bioservices last closed at $12.49 and the price had moved by +99.2% over the past 365 days. In terms of relative price strength the Avid Bioservices share price has outperformed the S&P500 Index by +63.45% over the past year.
The overall consensus recommendation for Avid Bioservices is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAvid Bioservices does not currently pay a dividend.
Avid Bioservices does not currently pay a dividend.
Avid Bioservices does not currently pay a dividend.
To buy shares in Avid Bioservices you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $12.49, shares in Avid Bioservices had a market capitalisation of $801.14m.
Here are the trading details for Avid Bioservices:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CDMO
Based on an overall assessment of its quality, value and momentum Avid Bioservices is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Avid Bioservices is $12.50. That is 0.08% above the last closing price of $12.49.
Analysts covering Avid Bioservices currently have a consensus Earnings Per Share (EPS) forecast of -$0.34 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avid Bioservices. Over the past six months, its share price has outperformed the S&P500 Index by +4.59%.
As of the last closing price of $12.49, shares in Avid Bioservices were trading +22.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Avid Bioservices PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Avid Bioservices' management team is headed by:
- Joseph Carleone - NEC
- Nicholas Green - PRE
- Daniel Hart - CFO
- Richard Richieri - COO
- Mark Ziebell - VPR
- Matthew Kwietniak - OTH
- Richard Hancock - DRC
- Esther Alegria - IND
- Catherine Mackey - IND
- Gregory Sargen - IND
- Jeanne Thoma - IND